Bringing the fundamentals into focus…
Back to Arcutis Biotherapeutics, Inc.
How Arcutis Biotherapeutics, Inc. stacks up
ARQT · against 264 other Healthcare companies of similar size
Valuation
38/ 100
Below the middle of the pack.
Ranked #188 of 265 · scores higher than 29% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 30–39, including ARQT · Click a bar to see the companies
Why valuation scores 38?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 65% of peers. EBITDA yield: 1.0% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 0.7% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.0% vs peer median 0.0%
Metric by metric
Position: dot = ARQT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ARQT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 260 reported | 0.7% | 2.5% | 34% | 30% | |
| EBITDA yieldHigher is better · 259 reported | 0.9% | 4.8% | 27% | 50% | |
| Free cash flow yieldHigher is better · 141 reported | 1.0% | 0.9% | 52% | 20% | |
| Book yieldHigher is better · 258 reported | 5.5% | 27.2% | 9% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ARQT| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 5 | 21.1B HKD (≈$2.7B) | 98 | 67 | |
| 180 | 4.4B AUD (≈$2.9B) | 40 | 51 | |
| 185 | 18.9B CNY (≈$2.6B) | 39 | 49 | |
| 185 | 27.6B SEK (≈$2.8B) | 39 | 76 | |
| 185 | 2.6B USD | 39 | 32 | |
| 188 | 4.0B USD | 38 | 56 | |
| 189 | 5.2B USD | 37 | 74 | |
| 189 | 2.7B USD | 37 | 44 | |
| 191 | 18.7B CNY (≈$2.6B) | 36 | 51 | |
| 191 | 3.1B USD | 36 | 53 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score